Understanding the regulation of β-catenin expression and activity in colorectal cancer carcinogenesis: beyond destruction complex
- PMID: 34426910
- DOI: 10.1007/s12094-021-02686-7
Understanding the regulation of β-catenin expression and activity in colorectal cancer carcinogenesis: beyond destruction complex
Abstract
Aberrant Wnt/β-catenin signaling is central to colorectal cancer carcinogenesis. The well-known potential of targeting the canonical Wnt signaling pathway for the treatment of CRC is largely attributed to the ability of this pathway to regulate various cellular processes such as cell proliferation, metastasis, drug resistance, immune response, apoptosis, and cellular metabolism. However, with the current approach of targeting this pathway, none of the Wnt-targeted agents have been successfully implicated in clinical practice. Instead of using classical approaches to target this pathway, there is a growing need to find new and modified approaches to achieve the same. For this, a better understanding of the regulation of β-catenin, a major effector of the canonical Wnt pathway is a must. The present review addresses the importance of understanding the regulation of β-catenin beyond the destruction complex. Few recently discovered β-catenin regulators such as ZNF281, TTPAL, AGR2, ARHGAP25, TREM2, and TIPE1 showed significant potential in regulating the development of CRC through modulation of the Wnt/β-catenin signaling pathway in both in vitro and in vivo studies. Although the expression and activity of β-catenin is influenced by many protein regulators, the abovementioned proteins not only influence its expression and activation but are also directly involved in the development of CRC and various other solid tumors. Therefore, we hypothesise that focusing the current research on finding the detailed mechanism of action of these regulators may assist in providing with a better treatment approach or improve the current therapeutic regimens.
Keywords: Colorectal cancer; Metastasis; Wnt signalling; β-catenin.
© 2021. Federación de Sociedades Españolas de Oncología (FESEO).
Similar articles
-
TTPAL Promotes Colorectal Tumorigenesis by Stabilizing TRIP6 to Activate Wnt/β-Catenin Signaling.Cancer Res. 2019 Jul 1;79(13):3332-3346. doi: 10.1158/0008-5472.CAN-18-2986. Epub 2019 Apr 24. Cancer Res. 2019. PMID: 31018940
-
Transcriptional Regulation of Wnt/β-Catenin Pathway in Colorectal Cancer.Cells. 2020 Sep 19;9(9):2125. doi: 10.3390/cells9092125. Cells. 2020. PMID: 32961708 Free PMC article. Review.
-
ARHGAP25: A negative regulator of colorectal cancer (CRC) metastasis via the Wnt/β-catenin pathway.Eur J Pharmacol. 2019 Sep 5;858:172476. doi: 10.1016/j.ejphar.2019.172476. Epub 2019 Jun 19. Eur J Pharmacol. 2019. PMID: 31228451
-
Therapeutic potential of targeting the Wnt/β-catenin signaling pathway in colorectal cancer.Biomed Pharmacother. 2019 Feb;110:473-481. doi: 10.1016/j.biopha.2018.11.082. Epub 2018 Dec 6. Biomed Pharmacother. 2019. PMID: 30530050 Review.
-
RNF6 promotes colorectal cancer invasion and migration via the Wnt/β-catenin pathway by inhibiting GSK3β activity.Pathol Res Pract. 2021 Sep;225:153545. doi: 10.1016/j.prp.2021.153545. Epub 2021 Jul 10. Pathol Res Pract. 2021. PMID: 34352441
Cited by
-
The association of Wnt-signalling and EMT markers with clinical characteristics in women with endometrial cancer.Front Oncol. 2023 Mar 8;13:1013463. doi: 10.3389/fonc.2023.1013463. eCollection 2023. Front Oncol. 2023. PMID: 36969079 Free PMC article.
-
PGM3 regulates beta-catenin activity to promote colorectal cancer cell progression.Exp Biol Med (Maywood). 2022 Sep;247(17):1518-1528. doi: 10.1177/15353702221101810. Epub 2022 Jun 20. Exp Biol Med (Maywood). 2022. PMID: 35723049 Free PMC article.
-
Phosphorylation-Dependent Regulation of WNT/Beta-Catenin Signaling.Front Oncol. 2022 Mar 14;12:858782. doi: 10.3389/fonc.2022.858782. eCollection 2022. Front Oncol. 2022. PMID: 35359365 Free PMC article. Review.
-
p130Cas Is Correlated with EREG Expression and a Prognostic Factor Depending on Colorectal Cancer Stage and Localization Reducing FOLFIRI Efficacy.Int J Mol Sci. 2021 Nov 16;22(22):12364. doi: 10.3390/ijms222212364. Int J Mol Sci. 2021. PMID: 34830244 Free PMC article.
References
-
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. https://doi.org/10.3322/caac.21492 . - DOI - PubMed - PMC
-
- Chakravarthi BVSK, Nepal S, Varambally S. Genomic and epigenomic alterations in cancer. Am J Pathol. 2016;186:1724–35. https://doi.org/10.1016/j.ajpath.2016.02.023 . - DOI - PubMed - PMC
-
- La Vecchia S, Sebastián C. Metabolic pathways regulating colorectal cancer initiation and progression. Semin Cell Dev Biol. 2019. https://doi.org/10.1016/j.semcdb.2019.05.018 . - DOI - PubMed
-
- Smith G, Carey FA, Beattie J, Wilkie MJV, Lightfoot TJ, Coxhead J, Garner RC, Steele RJC, Wolf CR. Mutations in APC, Kirsten-ras, and p53–alternative genetic pathways to colorectal cancer. Proc Natl Acad Sci USA. 2002;99:9433–8. https://doi.org/10.1073/pnas.122612899 . - DOI - PubMed - PMC
-
- Müller MF, Ibrahim AEK, Arends MJ. Molecular pathological classification of colorectal cancer. Virchows Arch. 2016;469:125–34. https://doi.org/10.1007/s00428-016-1956-3 . - DOI - PubMed - PMC
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
